Document 0278
 DOCN  M94A0278
 TI    Controversial aspects in the management of vulvovaginal candidiasis.
 DT    9412
 AU    Sobel JD; Division of Infectious Disease, Wayne State University School
       of; Medicine, Detroit, MI.
 SO    J Am Acad Dermatol. 1994 Sep;31(3 Pt 2):S10-3. Unique Identifier :
       AIDSLINE MED/94358234
 AB    Numerous highly effective topical vaginal antimycotic agents are
       available that provide high cure rates with a favorable therapeutic side
       effect ratio. Recently three oral systemic azole agents have been added.
       Therapeutic options afford the opportunity of customizing therapy to
       achieve optimal cure rates. At the same time, several new complex issues
       have appeared that constitute new challenges to successful management,
       such as women with human immunodeficiency virus infection and infection
       caused by non-albicans Candida species and resistant strains of Candida
       albicans.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS  Acute Disease
       Administration, Oral  Administration, Topical  Antifungal
       Agents/*THERAPEUTIC USE  Candidiasis, Vulvovaginal/COMPLICATIONS/*DRUG
       THERAPY/IMMUNOLOGY  Dose-Response Relationship, Drug  Drug Resistance,
       Microbial  Female  Human  Male  Recurrence  JOURNAL ARTICLE  REVIEW
       REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).